NO20083968L - Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom - Google Patents

Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Info

Publication number
NO20083968L
NO20083968L NO20083968A NO20083968A NO20083968L NO 20083968 L NO20083968 L NO 20083968L NO 20083968 A NO20083968 A NO 20083968A NO 20083968 A NO20083968 A NO 20083968A NO 20083968 L NO20083968 L NO 20083968L
Authority
NO
Norway
Prior art keywords
prevent
receptor antagonists
adenosine receptor
hepatic disease
treat hepatic
Prior art date
Application number
NO20083968A
Other languages
English (en)
Norwegian (no)
Inventor
Dewan Zeng
Luiz Belardinelli
Hongyan Zhong
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20083968L publication Critical patent/NO20083968L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20083968A 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom NO20083968L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20083968L true NO20083968L (no) 2008-12-15

Family

ID=38514256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083968A NO20083968L (no) 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Country Status (14)

Country Link
US (4) US7795268B2 (hr)
EP (1) EP1996201A2 (hr)
JP (2) JP5250848B2 (hr)
KR (1) KR101428113B1 (hr)
CN (1) CN101405003B (hr)
AU (1) AU2007227021B2 (hr)
CA (2) CA2646333C (hr)
IL (1) IL194158A0 (hr)
MX (1) MX2008011828A (hr)
NO (1) NO20083968L (hr)
NZ (1) NZ571324A (hr)
RU (1) RU2457842C2 (hr)
WO (1) WO2007109547A2 (hr)
ZA (1) ZA200807894B (hr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
PL1658291T3 (pl) * 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
NZ571324A (en) 2006-03-17 2011-07-29 Gilead Palo Alto Inc Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
ATE500263T1 (de) * 2006-06-27 2011-03-15 Cbt Dev Ltd Neue 2',3'-methylidenacetyladenosine prodrugs zur verwendung als adenosinrezeptoragonisten
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3878462A1 (en) 2015-10-29 2021-09-15 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of cancer radiotherapy
US20200377863A1 (en) 2016-02-10 2020-12-03 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
KR101709307B1 (ko) 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
JP7189155B2 (ja) * 2017-05-17 2022-12-13 アーカス バイオサイエンシズ インコーポレイティド 癌関連障害の治療のためのキナゾリン－ピラゾール誘導体
JP2020532541A (ja) * 2017-08-31 2020-11-12 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法
WO2019173380A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2020023846A1 (en) 2018-07-27 2020-01-30 Arcus Biosciences, Inc. Pyridone a2r antagonists
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
CA2454654A1 (en) * 2002-05-30 2003-12-11 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
NZ571324A (en) * 2006-03-17 2011-07-29 Gilead Palo Alto Inc Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists

Also Published As

Publication number Publication date
CA2849661A1 (en) 2007-09-27
KR20080107416A (ko) 2008-12-10
CN101405003B (zh) 2011-05-11
MX2008011828A (es) 2008-09-29
EP1996201A2 (en) 2008-12-03
US20070219221A1 (en) 2007-09-20
US7795268B2 (en) 2010-09-14
AU2007227021B2 (en) 2012-12-20
IL194158A0 (en) 2009-08-03
ZA200807894B (en) 2009-05-27
WO2007109547A3 (en) 2007-11-29
KR101428113B1 (ko) 2014-08-07
CA2646333A1 (en) 2007-09-27
NZ571324A (en) 2011-07-29
RU2457842C2 (ru) 2012-08-10
JP2013049719A (ja) 2013-03-14
CA2646333C (en) 2014-06-17
CN101405003A (zh) 2009-04-08
US20120220608A1 (en) 2012-08-30
AU2007227021A1 (en) 2007-09-27
US20110184002A1 (en) 2011-07-28
RU2008137279A (ru) 2010-03-27
JP2009530413A (ja) 2009-08-27
JP5250848B2 (ja) 2013-07-31
WO2007109547A2 (en) 2007-09-27
US20140243358A1 (en) 2014-08-28
US8188099B2 (en) 2012-05-29
US8609671B2 (en) 2013-12-17

Similar Documents

Publication Publication Date Title
NO20083968L (no) Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom
Qaddir et al. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies
NO20072733L (no) Doseformer
WO2010034670A3 (en) Host cell kinases as targets for antiviral therapies against hcv infection
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
EA200900297A1 (ru) Ингибиторы вируса гепатита с
MY169275A (en) Method of immunization against the four serotypes of dengue
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
WO2014089296A3 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
NO20092585L (no) Forbindelser og farmasoytiske sammensetninger for behandling av virale infeksjoner
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
NO20084411L (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application